Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation : I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022
IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period).MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition.ResultsWe included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively.ConclusionsOur results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin - 28(2023), 47 vom: 23. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rose, Angela Mc [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 12.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2807/1560-7917.ES.2023.28.47.2300187 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364889241 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364889241 | ||
| 003 | DE-627 | ||
| 005 | 20240114234305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2807/1560-7917.ES.2023.28.47.2300187 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1257.xml |
| 035 | |a (DE-627)NLM364889241 | ||
| 035 | |a (NLM)37997665 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rose, Angela Mc |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation |b I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 12.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period).MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition.ResultsWe included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively.ConclusionsOur results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Europe | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a hospital | |
| 650 | 4 | |a omicron | |
| 650 | 4 | |a vaccine effectiveness | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Nicolay, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Sandonis Martín, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Mazagatos, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Petrović, Goranka |e verfasserin |4 aut | |
| 700 | 1 | |a Baruch, Joaquin |e verfasserin |4 aut | |
| 700 | 1 | |a Denayer, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Seyler, Lucie |e verfasserin |4 aut | |
| 700 | 1 | |a Domegan, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Launay, Odile |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, Ausenda |e verfasserin |4 aut | |
| 700 | 1 | |a Burgui, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Vaikutyte, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Niessen, F Annabel |e verfasserin |4 aut | |
| 700 | 1 | |a Loghin, Isabela I |e verfasserin |4 aut | |
| 700 | 1 | |a Husa, Petr |e verfasserin |4 aut | |
| 700 | 1 | |a Aouali, Nassera |e verfasserin |4 aut | |
| 700 | 1 | |a Panagiotakopoulos, George |e verfasserin |4 aut | |
| 700 | 1 | |a Tolksdorf, Kristin |e verfasserin |4 aut | |
| 700 | 1 | |a Horváth, Judit Krisztina |e verfasserin |4 aut | |
| 700 | 1 | |a Howard, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Pozo, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Gallardo, Virtudes |e verfasserin |4 aut | |
| 700 | 1 | |a Nonković, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Džiugytė, Aušra |e verfasserin |4 aut | |
| 700 | 1 | |a Bossuyt, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Demuyser, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Duffy, Róisín |e verfasserin |4 aut | |
| 700 | 1 | |a Luong Nguyen, Liem Binh |e verfasserin |4 aut | |
| 700 | 1 | |a Kislaya, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Baz, Iván |e verfasserin |4 aut | |
| 700 | 1 | |a Gefenaite, Giedre |e verfasserin |4 aut | |
| 700 | 1 | |a Knol, Mirjam J |e verfasserin |4 aut | |
| 700 | 1 | |a Popescu, Corneliu |e verfasserin |4 aut | |
| 700 | 1 | |a Součková, Lenka |e verfasserin |4 aut | |
| 700 | 1 | |a Simon, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Michelaki, Stella |e verfasserin |4 aut | |
| 700 | 1 | |a Reiche, Janine |e verfasserin |4 aut | |
| 700 | 1 | |a Ferenczi, Annamária |e verfasserin |4 aut | |
| 700 | 1 | |a Delgado-Sanz, Concepción |e verfasserin |4 aut | |
| 700 | 1 | |a Lovrić Makarić, Zvjezdana |e verfasserin |4 aut | |
| 700 | 1 | |a Cauchi, John Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Barbezange, Cyril |e verfasserin |4 aut | |
| 700 | 1 | |a Van Nedervelde, Els |e verfasserin |4 aut | |
| 700 | 1 | |a O'Donnell, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Durier, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Guiomar, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Castilla, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Jonikaite, Indrė |e verfasserin |4 aut | |
| 700 | 1 | |a Bruijning-Verhagen, Patricia Cjl |e verfasserin |4 aut | |
| 700 | 1 | |a Lazar, Mihaela |e verfasserin |4 aut | |
| 700 | 1 | |a Demlová, Regina |e verfasserin |4 aut | |
| 700 | 1 | |a Wirtz, Gil |e verfasserin |4 aut | |
| 700 | 1 | |a Amerali, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Dürrwald, Ralf |e verfasserin |4 aut | |
| 700 | 1 | |a Kunstár, Mihály Pál |e verfasserin |4 aut | |
| 700 | 1 | |a Kissling, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Bacci, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Valenciano, Marta |e verfasserin |4 aut | |
| 700 | 0 | |a I-MOVE-COVID-19 hospital study team |e verfasserin |4 aut | |
| 700 | 0 | |a VEBIS hospital study team |e verfasserin |4 aut | |
| 700 | 0 | |a Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to authors above) |e verfasserin |4 aut | |
| 700 | 1 | |a Karabuva, Svjetlana |e investigator |4 oth | |
| 700 | 1 | |a Mladinov, Suzana |e investigator |4 oth | |
| 700 | 1 | |a Markić, Joško |e investigator |4 oth | |
| 700 | 1 | |a Petrić, Petra Tomaš |e investigator |4 oth | |
| 700 | 1 | |a Tabain, Irena |e investigator |4 oth | |
| 700 | 1 | |a Ilić, Maja |e investigator |4 oth | |
| 700 | 1 | |a Mlinarić, Ivan |e investigator |4 oth | |
| 700 | 1 | |a Smoljo, Petra |e investigator |4 oth | |
| 700 | 1 | |a Novosel, Iva Pem |e investigator |4 oth | |
| 700 | 1 | |a Melillo, Tanya |e investigator |4 oth | |
| 700 | 1 | |a Borg, Maria-Louise |e investigator |4 oth | |
| 700 | 1 | |a Lissoir, Benédicte |e investigator |4 oth | |
| 700 | 1 | |a Holemans, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Hainaut, Marc |e investigator |4 oth | |
| 700 | 1 | |a Dauby, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Delaere, Benedicte |e investigator |4 oth | |
| 700 | 1 | |a Bourgeois, Marc |e investigator |4 oth | |
| 700 | 1 | |a Petit, Evelyn |e investigator |4 oth | |
| 700 | 1 | |a Reynders, Marijke |e investigator |4 oth | |
| 700 | 1 | |a Jouck, Door |e investigator |4 oth | |
| 700 | 1 | |a Magerman, Koen |e investigator |4 oth | |
| 700 | 1 | |a Bleyen, Marieke |e investigator |4 oth | |
| 700 | 1 | |a Vermeulen, Melissa |e investigator |4 oth | |
| 700 | 1 | |a Fierens, Sébastien |e investigator |4 oth | |
| 700 | 1 | |a Dufrasne, François |e investigator |4 oth | |
| 700 | 1 | |a Daelemans, Siel |e investigator |4 oth | |
| 700 | 1 | |a Al Kerwi, Ala'a |e investigator |4 oth | |
| 700 | 1 | |a Berthet, Francoise |e investigator |4 oth | |
| 700 | 1 | |a Fagherazzi, Guy |e investigator |4 oth | |
| 700 | 1 | |a Alexandre, Myriam |e investigator |4 oth | |
| 700 | 1 | |a Bennett, Charlene |e investigator |4 oth | |
| 700 | 1 | |a Christle, Jim |e investigator |4 oth | |
| 700 | 1 | |a Connell, Jeff |e investigator |4 oth | |
| 700 | 1 | |a Doran, Peter |e investigator |4 oth | |
| 700 | 1 | |a Feeney, Laura |e investigator |4 oth | |
| 700 | 1 | |a Maharjan, Binita |e investigator |4 oth | |
| 700 | 1 | |a McDermott, Sinead |e investigator |4 oth | |
| 700 | 1 | |a McNamara, Rosa |e investigator |4 oth | |
| 700 | 1 | |a Nurdin, Nadra |e investigator |4 oth | |
| 700 | 1 | |a Lesieur, Zineb |e investigator |4 oth | |
| 700 | 1 | |a Cissé, Salif Mamadou |e investigator |4 oth | |
| 700 | 1 | |a L'Honneur, Anne-Sophie |e investigator |4 oth | |
| 700 | 1 | |a Duval, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Costa, Yolande |e investigator |4 oth | |
| 700 | 1 | |a Nadhira, Fidouh |e investigator |4 oth | |
| 700 | 1 | |a Galtier, Florence |e investigator |4 oth | |
| 700 | 1 | |a Crantelle, Laura |e investigator |4 oth | |
| 700 | 1 | |a Foulongne, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Vanhems, Phillipe |e investigator |4 oth | |
| 700 | 1 | |a Amour, Sélilah |e investigator |4 oth | |
| 700 | 1 | |a Lina, Bruno |e investigator |4 oth | |
| 700 | 1 | |a Lainé, Fabrice |e investigator |4 oth | |
| 700 | 1 | |a Gallais, Laetitia |e investigator |4 oth | |
| 700 | 1 | |a Lagathu, Gisèle |e investigator |4 oth | |
| 700 | 1 | |a Maisa, Anna |e investigator |4 oth | |
| 700 | 1 | |a Bernard-Stoecklin, Sibylle |e investigator |4 oth | |
| 700 | 1 | |a Saidi, Yacine |e investigator |4 oth | |
| 700 | 1 | |a Durier, Christine |e investigator |4 oth | |
| 700 | 1 | |a Bauer, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Rodrigues, Ana Paula |e investigator |4 oth | |
| 700 | 1 | |a Silva, Adriana |e investigator |4 oth | |
| 700 | 1 | |a Gomez, Verónica |e investigator |4 oth | |
| 700 | 1 | |a Tavares, Margarida |e investigator |4 oth | |
| 700 | 1 | |a Pereira, Débora |e investigator |4 oth | |
| 700 | 1 | |a Manata, Maria José |e investigator |4 oth | |
| 700 | 1 | |a Gruner, Heidi |e investigator |4 oth | |
| 700 | 1 | |a Almeida, André |e investigator |4 oth | |
| 700 | 1 | |a Pinto, Paula |e investigator |4 oth | |
| 700 | 1 | |a Bárbara, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Miqueleiz, Ana |e investigator |4 oth | |
| 700 | 1 | |a Navascués, Ana |e investigator |4 oth | |
| 700 | 1 | |a Trobajo-Sanmartín, Camino |e investigator |4 oth | |
| 700 | 1 | |a Ezpeleta, Carmen |e investigator |4 oth | |
| 700 | 1 | |a Egüés, Nerea |e investigator |4 oth | |
| 700 | 1 | |a Cenoz, Manuel García |e investigator |4 oth | |
| 700 | 1 | |a Ardanaz, Eva |e investigator |4 oth | |
| 700 | 1 | |a Guevara, Marcela |e investigator |4 oth | |
| 700 | 1 | |a Moreno-Iribas, Conchi |e investigator |4 oth | |
| 700 | 1 | |a Casado, Itziar |e investigator |4 oth | |
| 700 | 1 | |a Mickiene, Auksė |e investigator |4 oth | |
| 700 | 1 | |a Kuliese, Monika |e investigator |4 oth | |
| 700 | 1 | |a Orlíková, Hana |e investigator |4 oth | |
| 700 | 1 | |a Dorobat, Carmen Mihaela |e investigator |4 oth | |
| 700 | 1 | |a Manciuc, Carmen |e investigator |4 oth | |
| 700 | 1 | |a Florescu, Simin Aysel |e investigator |4 oth | |
| 700 | 1 | |a Marin, Alexandru |e investigator |4 oth | |
| 700 | 1 | |a Dinu, Sorin |e investigator |4 oth | |
| 700 | 1 | |a Pascu, Catalina |e investigator |4 oth | |
| 700 | 1 | |a Ivanciuc, Alina |e investigator |4 oth | |
| 700 | 1 | |a Bistriceanu, Iulia |e investigator |4 oth | |
| 700 | 1 | |a Oprea, Mihaela |e investigator |4 oth | |
| 700 | 1 | |a Mihai, Maria Elena |e investigator |4 oth | |
| 700 | 1 | |a Buda, Silke |e investigator |4 oth | |
| 700 | 1 | |a Preuss, Ute |e investigator |4 oth | |
| 700 | 1 | |a Wedde, Marianne |e investigator |4 oth | |
| 700 | 1 | |a Oroszi, Beatrix |e investigator |4 oth | |
| 700 | 1 | |a Krisztalovics, Katalin |e investigator |4 oth | |
| 700 | 1 | |a Túri, Gergő |e investigator |4 oth | |
| 700 | 1 | |a Kristóf, Katalin |e investigator |4 oth | |
| 700 | 1 | |a Varga, Csaba |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin |d 1995 |g 28(2023), 47 vom: 23. Nov. |w (DE-627)NLM115683283 |x 1560-7917 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:47 |g day:23 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2807/1560-7917.ES.2023.28.47.2300187 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 47 |b 23 |c 11 | ||